Switch to:
Also traded in: Germany, Israel, Mexico, Switzerland, USA

Latest Guru Trades with TEVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Teva Pharmaceutical Industries Ltd

SymbolPriceYieldDescription
TEVVF858.006.307 % Conv.Cum.Pfd Shs Mandatory Conv. 15.12.2018

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:OTCPK:TKPYY, NYSE:ZTS, NAS:MYL, OTCPK:ESALY, OTCPK:SGIOY, OTCPK:MKGAY, NYSE:PRGO, OTCPK:APNHY, OTCPK:MTZPY, NYSE:VRX, OTCPK:HLUYY, OTCPK:HKMPF, NYSE:MNK, NYSE:RDY, OTCPK:DNPUF, OTCPK:MDABY, OTCPK:SFOSF, OTCPK:ORINY, NYSE:TARO, OTCPK:IPSEY » details
Traded in other countries:TEV.Germany, TEVA.Israel, TEVAN.Mexico, TEVA.Switzerland, TEVJF.USA,
Teva Pharmaceutical Industries Ltd develops, produces and markets generic, branded & OTC medicines. Some of its products are Copaxone, Azilect & Provigil.

Teva Pharmaceutical Industries Ltd was incorporated in Israel on February 13, 1944. The Company manufactures generic pharmaceutical products. It operates in business in two segments generic and specialty medicines. The generics segment develops, manufactures, sells and distributes generic or branded generic medicines as well as active pharmaceutical ingredients ("API"). The specialty segment engages in the development, manufacture, sale and distribution of branded specialty medicines such as those for central nervous system and respiratory indications, as well as those marketed in the women's health, oncology and other specialty businesses. Its other activities include the over-the-counter ("OTC") medicines business, distribution activity mainly in Israel and Hungary and medical devices. The OTC activity is mainly conducted through a joint venture with P&G, which combines Company's production capabilities and market reach with P&G's marketing expertise and expansive platform. It has market presence in the United States, Europe and other markets. The Generic medicines include chemical and therapeutic equivalents of originator medicines in dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. The Specialty medicines include several franchises in the core therapeutic areas of CNS medicines such as Copaxone, Azilect, Nuvigil and Zecuity and of respiratory medicines such as ProAir HFA and QVAR. It also includes other therapeutic areas, such as oncology medicines, including Treanda, women's health and selected other areas. The Company is subject to extensive regulation by the United States federal government, principally by the FDA and the Drug Enforcement Administration ("DEA").

Guru Investment Theses on Teva Pharmaceutical Industries Ltd

John Keeley Comments on Teva Pharmaceuticals - Apr 26, 2016

Teva Pharmaceuticals (NYSE:TEVA) also had a challenging quarter. Although earnings were in-line with expectations, the company announced that its acquisition of Allergan’s generic pharmaceutical business would be delayed. Subsequent to the failure of the Pfizer/Allergan merger due to the proposed tax inversion regulatory changes, Teva announced that its acquisition of Allergan’s generic business remains on track to close in the second quarter of 2016.



From Keeley All Cap Value Fund first quarter 2016 commentary.



Check out John Keeley latest stock trades

Bernard Horn Comments on Teva Pharmaceutical - Mar 21, 2016

Teva Pharmaceutical (NYSE:TEVA) achieved strong profits, noting better-than-expected Copaxone sales. The company’s strategic initiatives, including the takeover of Allergan’s Actavis generic drug business and the joint venture with Takeda in Japan, were well received. This will further cement Teva’s position as the global leader in generics and help the company negotiate with its customers.

From Bernard Horn (Trades, Portfolio)'s Global Value Fund annual letter 2015.



Check out Bernard Horn latest stock trades

Vanguard Health Care Fund Comments on Teva Pharmaceutical Industries Ltd - Mar 27, 2015

We trimmed into strength our position in Teva (TEVA), an Israel-based global biopharmaceutical company specializing in generic formulations. The stock rose substantially on a combination of speculation around M&A in the sector, enthusiasm for the new CEO, and the strong conversion of once-daily Copaxone to the three-times-a-week version.

From Vanguard Health Care Fund (Trades, Portfolio) 2014 Annual Report

Check out Vanguard Health Care Fund latest stock trades

Top Ranked Articles about Teva Pharmaceutical Industries Ltd

Allergan: An Undervalued Powerhouse After selling its generic units to Teva, Allergan has room for growth
Allergan (NYSE:AGN) is one of the largest pharmaceutical powerhouses, operating in many areas including eye care, facial aesthetics, plastic surgery, skin care and neuroscience and urology. Allergan’s history is quite interesting as the company has grown via many big acquisitions. Read more...
Andreas Halvorsen Buys Facebook, Amazon, MasterCard Guru's largest 1st-quarter buys
Andreas Halvorsen (Trades, Portfolio) is a founding partner of Viking Global Investors LP and currently serves as its CIO. During the first quarter he bought shares in the following stocks: Read more...
John Keeley Comments on Teva Pharmaceuticals Guru stock highlight
Teva Pharmaceuticals (NYSE:TEVA) also had a challenging quarter. Although earnings were in-line with expectations, the company announced that its acquisition of Allergan’s generic pharmaceutical business would be delayed. Subsequent to the failure of the Pfizer/Allergan merger due to the proposed tax inversion regulatory changes, Teva announced that its acquisition of Allergan’s generic business remains on track to close in the second quarter of 2016. Read more...
Health Care Investor Larry Robbins Buys HCA Holdings, Cigna Top 4th quarter buys from Glenview Capital founder
Glenview Capital Management, founded in 2000 by Larry Robbins (Trades, Portfolio), is a privately held investment management firm. During the fourth quarter, he bought shares in many stocks, including the following.  Read more...
Bernard Horn Comments on Teva Pharmaceutical Guru stock highlight
Teva Pharmaceutical (NYSE:TEVA) achieved strong profits, noting better-than-expected Copaxone sales. The company’s strategic initiatives, including the takeover of Allergan’s Actavis generic drug business and the joint venture with Takeda in Japan, were well received. This will further cement Teva’s position as the global leader in generics and help the company negotiate with its customers. Read more...
John Paulson Raises Stake in Valeant, Teva Pharmaceutical Event and distressed strategies investor ups Valeant stake by 50%
John Paulson (Trades, Portfolio) is the president and portfolio manager of Paulson & Co. Inc. Paulson was ranked by Absolute Return Magazine as the third-largest hedge fund in the world managing approximately $29 billion in merger, event and distressed strategies. During the fourth quarter, the guru bought the following stocks. Read more...
Andreas Halvorsen Raises Stake in Teva Pharmaceutical Guru reduces holdings in Netflix, Walgreens Boots Alliance, MasterCard, Alphabet
Andreas Halvorsen (Trades, Portfolio), founding partner and CIO of Viking Global Investors LP, added two dozen stakes to his portfolio in the fourth quarter, but his most noteworthy activity was the increase of his stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), an Israeli pharmaceutical company, by more than 182%. Read more...
Julian Robertson Buys 8 New Stakes in 4th Quarter Guru's investments include Teva Pharmaceutical, Dollar Tree
Julian Robertson (Trades, Portfolio) of Tiger Management made eight new buys in a wide range of sectors in the fourth quarter. His preferred sectors, Technology and Healthcare, were well represented. Read more...
CME Group Among Guru Stocks With Growing Yield Investment ideas with high dividend yields
The following are companies with high and growing dividend yields that gurus are buying according to GuruFocus' All-in-One Screener. Read more...
John Griffin Invests in Teva Pharmaceutical Guru adds to holdings in Autodesk and Allergan in 4th quarter
John Griffin (Trades, Portfolio), president of Blue Ridge Capital, made five new buys in the fourth quarter, three of which had impacts on his portfolio exceeding 1.5%. Read more...
» More Articles for TEVA

Ratios

vs
industry
vs
history
P/E(ttm) 33.66
TEVA's P/E(ttm) is ranked lower than
60% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.55 vs. TEVA: 33.66 )
Ranked among companies with meaningful P/E(ttm) only.
TEVA' s P/E(ttm) Range Over the Past 10 Years
Min: 10.49  Med: 20.67 Max: 938.25
Current: 33.66
10.49
938.25
Forward P/E 9.71
TEVA's Forward P/E is ranked higher than
82% of the 65 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.89 vs. TEVA: 9.71 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 33.66
TEVA's PE(NRI) is ranked lower than
60% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.41 vs. TEVA: 33.66 )
Ranked among companies with meaningful PE(NRI) only.
TEVA' s PE(NRI) Range Over the Past 10 Years
Min: 10.49  Med: 20.67 Max: 938.25
Current: 33.66
10.49
938.25
Price/Owner Earnings (ttm) 21.36
TEVA's Price/Owner Earnings (ttm) is ranked higher than
70% of the 279 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.58 vs. TEVA: 21.36 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
TEVA' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.13  Med: 17.14 Max: 67.1
Current: 21.36
9.13
67.1
P/B 1.75
TEVA's P/B is ranked higher than
70% of the 690 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.04 vs. TEVA: 1.75 )
Ranked among companies with meaningful P/B only.
TEVA' s P/B Range Over the Past 10 Years
Min: 1.36  Med: 2.25 Max: 4.81
Current: 1.75
1.36
4.81
P/S 2.31
TEVA's P/S is ranked higher than
56% of the 690 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.78 vs. TEVA: 2.31 )
Ranked among companies with meaningful P/S only.
TEVA' s P/S Range Over the Past 10 Years
Min: 1.58  Med: 2.93 Max: 5.83
Current: 2.31
1.58
5.83
PFCF 10.47
TEVA's PFCF is ranked higher than
85% of the 192 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.70 vs. TEVA: 10.47 )
Ranked among companies with meaningful PFCF only.
TEVA' s PFCF Range Over the Past 10 Years
Min: 8.46  Med: 16.35 Max: 81.46
Current: 10.47
8.46
81.46
POCF 8.89
TEVA's POCF is ranked higher than
81% of the 248 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.32 vs. TEVA: 8.89 )
Ranked among companies with meaningful POCF only.
TEVA' s POCF Range Over the Past 10 Years
Min: 6.58  Med: 11.7 Max: 23.43
Current: 8.89
6.58
23.43
EV-to-EBIT 27.03
TEVA's EV-to-EBIT is ranked lower than
62% of the 524 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.32 vs. TEVA: 27.03 )
Ranked among companies with meaningful EV-to-EBIT only.
TEVA' s EV-to-EBIT Range Over the Past 10 Years
Min: 11.4  Med: 21.1 Max: 991
Current: 27.03
11.4
991
EV-to-EBITDA 16.73
TEVA's EV-to-EBITDA is ranked higher than
52% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.57 vs. TEVA: 16.73 )
Ranked among companies with meaningful EV-to-EBITDA only.
TEVA' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9  Med: 17.2 Max: 290.6
Current: 16.73
9
290.6
PEG 13.76
TEVA's PEG is ranked lower than
91% of the 289 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.98 vs. TEVA: 13.76 )
Ranked among companies with meaningful PEG only.
TEVA' s PEG Range Over the Past 10 Years
Min: 0.34  Med: 1.12 Max: 119.22
Current: 13.76
0.34
119.22
Shiller P/E 20.10
TEVA's Shiller P/E is ranked higher than
84% of the 154 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 51.01 vs. TEVA: 20.10 )
Ranked among companies with meaningful Shiller P/E only.
TEVA' s Shiller P/E Range Over the Past 10 Years
Min: 18.44  Med: 28.63 Max: 61.22
Current: 20.1
18.44
61.22
Current Ratio 1.27
TEVA's Current Ratio is ranked lower than
79% of the 672 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. TEVA: 1.27 )
Ranked among companies with meaningful Current Ratio only.
TEVA' s Current Ratio Range Over the Past 10 Years
Min: 0.92  Med: 1.59 Max: 2.95
Current: 1.27
0.92
2.95
Quick Ratio 1.00
TEVA's Quick Ratio is ranked lower than
76% of the 672 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. TEVA: 1.00 )
Ranked among companies with meaningful Quick Ratio only.
TEVA' s Quick Ratio Range Over the Past 10 Years
Min: 0.63  Med: 1.07 Max: 2.19
Current: 1
0.63
2.19
Days Inventory 178.11
TEVA's Days Inventory is ranked lower than
77% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.20 vs. TEVA: 178.11 )
Ranked among companies with meaningful Days Inventory only.
TEVA' s Days Inventory Range Over the Past 10 Years
Min: 131.65  Med: 186.4 Max: 208.14
Current: 178.11
131.65
208.14
Days Sales Outstanding 100.32
TEVA's Days Sales Outstanding is ranked lower than
68% of the 577 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.29 vs. TEVA: 100.32 )
Ranked among companies with meaningful Days Sales Outstanding only.
TEVA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 95.91  Med: 123.91 Max: 153.21
Current: 100.32
95.91
153.21

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.69
TEVA's Dividend Yield is ranked higher than
76% of the 610 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.57 vs. TEVA: 2.69 )
Ranked among companies with meaningful Dividend Yield only.
TEVA' s Dividend Yield Range Over the Past 10 Years
Min: 0.49  Med: 1.4 Max: 3.26
Current: 2.69
0.49
3.26
Dividend Payout 0.91
TEVA's Dividend Payout is ranked lower than
87% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.34 vs. TEVA: 0.91 )
Ranked among companies with meaningful Dividend Payout only.
TEVA' s Dividend Payout Range Over the Past 10 Years
Min: 0.04  Med: 0.14 Max: 2.83
Current: 0.91
0.04
2.83
Dividend Growth (3y) 9.80
TEVA's Dividend Growth (3y) is ranked higher than
56% of the 291 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.70 vs. TEVA: 9.80 )
Ranked among companies with meaningful Dividend Growth (3y) only.
TEVA' s Dividend Growth (3y) Range Over the Past 10 Years
Min: -6.7  Med: 27 Max: 80.9
Current: 9.8
-6.7
80.9
Forward Dividend Yield 2.69
TEVA's Forward Dividend Yield is ranked higher than
72% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.62 vs. TEVA: 2.69 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 5.53
TEVA's Yield on cost (5-Year) is ranked higher than
89% of the 717 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.13 vs. TEVA: 5.53 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
TEVA' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 1.01  Med: 2.88 Max: 6.7
Current: 5.53
1.01
6.7
3-Year Average Share Buyback Ratio -1.90
TEVA's 3-Year Average Share Buyback Ratio is ranked higher than
64% of the 424 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.40 vs. TEVA: -1.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TEVA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -12.6  Med: -1.9 Max: 1.2
Current: -1.9
-12.6
1.2

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 0.81
TEVA's Price/Projected FCF is ranked higher than
88% of the 299 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.42 vs. TEVA: 0.81 )
Ranked among companies with meaningful Price/Projected FCF only.
TEVA' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.66  Med: 1.5 Max: 29.19
Current: 0.81
0.66
29.19
Price/DCF (Earnings Based) 2.63
TEVA's Price/DCF (Earnings Based) is ranked lower than
86% of the 77 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.39 vs. TEVA: 2.63 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.79
TEVA's Price/Median PS Value is ranked higher than
80% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.15 vs. TEVA: 0.79 )
Ranked among companies with meaningful Price/Median PS Value only.
TEVA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.55  Med: 1.15 Max: 2.02
Current: 0.79
0.55
2.02
Earnings Yield (Greenblatt) (%) 3.68
TEVA's Earnings Yield (Greenblatt) (%) is ranked higher than
56% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. TEVA: 3.68 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TEVA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 4.7 Max: 8.8
Current: 3.68
0.1
8.8
Forward Rate of Return (Yacktman) (%) -0.62
TEVA's Forward Rate of Return (Yacktman) (%) is ranked lower than
66% of the 331 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.18 vs. TEVA: -0.62 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
TEVA' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -5  Med: 20.6 Max: 43.7
Current: -0.62
-5
43.7

More Statistics

Revenue (TTM) (Mil) $19,552
EPS (TTM) $ 1.50
Beta0.51
Short Percentage of Float1.51%
52-Week Range $48.01 - 66.55
Shares Outstanding (Mil)914.00

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 22,410 26,041 26,700
EPS ($) 5.21 6.00 6.35
EPS w/o NRI ($) 5.21 6.00 6.35
EPS Growth Rate
(3Y to 5Y Estimate)
7.60%
Dividends Per Share ($) 1.24 1.33 1.65
» More Articles for TEVA

Headlines

Articles On GuruFocus.com
Allergan: An Undervalued Powerhouse Aug 28 2016 
A Comprehensive Look at Dividend Growth Stock Valuations Sector by Sector: Part 2 Aug 26 2016 
Swiss Generics Manufacturer Has Strong 1st Half of Year Aug 22 2016 
Allergan Narrowly Beats Earnings, Thanks to Sales Surge Aug 09 2016 
Siegfried Holdings, Held by Tweedy Browne, Way Undervalued Jul 22 2016 
Andreas Halvorsen Buys Facebook, Amazon, MasterCard Jun 14 2016 
Growing Generic Drug Market a Good Opportuity for 2 India Firms May 30 2016 
Stocks Near 52-Week Lows May 26 2016 
John Keeley Comments on Teva Pharmaceuticals Apr 26 2016 
Pfizer-Allergen Merger Deal End Hurts Some Funds But Helps Many Apr 08 2016 

More From Other Websites
5 Health Care Stocks John Paulson Is Betting On in 2016 Aug 31 2016
MDxHealth and Teva Pharmaceuticals Sign Distribution Agreement for SelectMDx in Israel Aug 31 2016
Teva to Present New Respiratory Data at the 2016 European Respiratory Society (ERS) International... Aug 30 2016
Teva to Present New Respiratory Data at the 2016 European Respiratory Society (ERS) International... Aug 30 2016
Mylan To Launch Its Own EpiPen Generic Rival At Half Price Aug 29 2016
Analyst Recommendations for Akorn in 2016 Aug 29 2016
Teva to Host Generic Medicines Business Overview on September 9, 2016 Aug 29 2016
How Allergan Is Still Benefiting from Actavis Deal Aug 29 2016
Mylan's authorized generic EpiPen to be identical Aug 29 2016
[$$] Overheard: Mylan May Play Hero Aug 28 2016
[$$] Overheard Aug 28 2016
Billionaire John Paulson’s Favorite Healthcare Stocks Include The Latest Industry Punching Bag,... Aug 27 2016
FTC spells out new concerns over generic drug mergers Aug 26 2016
FTC Details Concerns on Generic Drug Company Mergers Aug 26 2016
After Mylan uproar, a generic EpiPen could hit the market in 2017 Aug 26 2016
Mylan Reacts to EpiPen Backlash Aug 26 2016
Mylan's EpiPen Price Increases Highlight Its Grip on the Market Aug 26 2016
US Patent and Trademark Office Invalidates Two Copaxone 40 Patents Aug 25 2016
Specialty Pharma: Never Mind the Pricing Controversy, Fundamentals Will Win Out Aug 25 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK